NewswireToday - /newswire/ -
Monrovia, CA, United States, 2012/03/09 - James F. List, Vice President, Full Development Lead, Dapagliflozin, Metabolics, R&D, Bristol-Myers Squibb will participate in the panel discussion at the 2nd Diabetes Summit to - GTCbio.com.
James F. List, Vice President, Metabolics, R&D, and Full Development Lead of Dapagliflozin, at Bristol-Myers Squibb will participate in the panel discussion called “Beyond HbA1c - Are there Better Endpoints for Clinical Trials?” at the 2nd Diabetes Summit to be held on April 19-20, 2012 in Boston, MA by GTC.
Other panelists in the panel discussion include Lane Desborough, Product Strategist at Medtronic, Claudia Graham, Ph.D., MPH, Vice President of Marketing & Global Access, Dexcom, and Solomon Steiner, Managing Partner at Steiner Ventures. The panel will discuss various topics such as why HbA1c may not be an ideal endpoint for clinical trials and what would it take to achieve a new standardized endpoint for clinical trials.
James F. List, M.D., Ph.D. is Vice President at Bristol-Myers Squibb. In 2011, Dr. List was appointed Full Development Lead for dapagliflozin, an SGLT-2 inhibitor being developed for the treatment of type 2 diabetes. He has responsibility to oversee the rigorous and efficient development and registration of the compound.
Dr. List joined Bristol-Myers Squibb in 2004 as Associate Director of Clinical Development and Evaluation in the area of metabolics, where he provided leadership for a number of global phase 2 and 3 studies, including pivotal studies in the development program of Onglyza.
Dr. List holds bachelors and masters degrees in Medical Microbiology and Philosophy of Science, respectively, from Stanford University. He received his M.D. and his Ph.D. in Microbiology and Immunology from the University of Minnesota. He received training in Internal Medicine at Brigham and Women’s Hospital, in Pediatrics from Children’s Hospital Boston, and in Endocrinology at Massachusetts General Hospital.
With more than 400 drug candidates for diabetes in active development and in light of the recent US Food and Drug Administration (FDA) guidance to assess cardiovascular risk in clinical trials, the burden to develop novel drugs is greater and the barrier for success has become higher than ever. What will be the next block-buster drug target for T1DM and T2DM? How does the recent FDA guidance affect our approach to develop new medications for diabetes? How do different size companies adapt the best strategy to be competitive in this field?
Come and join other diabetes experts at GTC’s 2nd Diabetes Summit and hear key thought-leader's opinions to these questions and many more. This important meeting will be held on April 19-20, 2012 in Boston, MA. The conference will bring together the leading experts on diabetes from both industry and academia to discuss novel targets for diabetes, lessons learned from current clinical drug development, and business strategies and opportunities under the current regulatory landscape.
The 2nd Diabetes Summit will consist of 2 tracks:
• 5th Diabetes Drug Discovery and Development.
• 2nd Diabetes Partnering & Deal Making.